Uncategorized

HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

Even before its billionaire owner made recent headlines by endorsing an antisemitic post and hurling an expletive at advertisers, biopharma companies had begun to find different uses for their advertisement budgets.

Engaged Capital is opposed to Nevro going after acquisitions that may jeopardize its core business, Bloomberg reported Monday.

Hospitals have lobbied against the site-neutral payment policies included in the bipartisan legislation.

Five Qualified Health Information Networks, or QHINs, completed the onboarding process and are ready for data exchange, with more companies in the pipeline.

The nonprofit systems are the latest to cut IT jobs this year as they navigate thin operating margins fueled by inflation and prolonged staffing shortages.

Medtronic and Johnson & Johnson are pursuing a market that leader Boston Scientific predicts could hit $6 billion by 2030.

  Si eres amante del deporte y quieres mejorar tu rendimiento al tiempo que cuidas del medio ambiente, presta atención. Te acercamos todos los detalles.   Cómo la fibra de carbono puede influir en tu juego o rendimiento deportivo   Un factor determinante muy a ten …

The sector has faced a wave of ransomware linked to the critical CitrixBleed vulnerability, which has led to major attacks from LockBit and other threat groups.

The findings — some of the first from new price transparency data — illustrate how overall economic inflation could be catching up to faster health cost growth.